IL7R Gene Transcript Detection for SIRS Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the risk of complications and mortality in patients with systemic inflammatory response syndrome (SIRS) or sepsis are impractical due to the need for active clinical investigations and require measurable markers that can be rapidly and readily assessed.
Innovation Solution
A method involving the detection and quantification of specific transcripts of the IL7R gene in biological samples to predict the risk of complications and mortality, allowing for personalized care and early intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical severity scores (SOFA, SAPSII) are used to evaluate patient risk, then comprehensive assessment of multiple physiological systems is achieved, but the method requires active clinical investigations and is not readily applicable at the bedside
Solution Approach 1:
The invention extracts a specific biomarker (sCD127) from the complex clinical assessment process. Instead of requiring comprehensive evaluation of multiple physiological parameters through active clinical investigations, the method isolates and measures a single soluble protein marker that can be rapidly quantified from blood samples, enabling bedside risk assessment while maintaining predictive accuracy for complications and mortality
Solution Approach 2:
The invention introduces sCD127 as an intermediary biomarker that mediates between the patient's immune status and the clinical outcome prediction. This soluble protein serves as a measurable proxy that reflects the underlying immunological competence without requiring direct assessment of complex clinical parameters, thus bridging the gap between comprehensive evaluation and rapid bedside testing
2Reliability
If comprehensive clinical parameters are investigated to assess patient condition, then accurate risk prediction is achieved, but the process is time-consuming and requires active clinical investigation
Solution Approach 1:
The method extracts the essential predictive information into a single measurable parameter (sCD127 concentration) that can be rapidly determined from routine blood samples. This eliminates the need for time-consuming active clinical investigations while maintaining the reliability of risk prediction for complications and mortality in SIRS patients
Solution Approach 2:
The biomarker sCD127 provides self-service by inherently containing the predictive information needed for risk assessment. The marker naturally reflects the patient's immune status and prognosis without requiring additional active investigations or complex clinical evaluations, thus enabling rapid assessment that does not delay care
Data Source
AI summary
A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.